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Summary. Background: Reliable markers and methods to
predict risk for thrombosis are essential to clinicalmanagement.
Objective: Using an integrated approach that deﬁnes an
individual’s comprehensive coagulation phenotypemight prove
valuable in identifying individuals at risk for experiencing a
thrombotic event. Methods: Using a numerical simulation
model, we generated tissue factor (TF) initiated thrombin
curves using coagulation factor levels from the Leiden Throm-
bophilia Study population and evaluated thrombotic risk, by
sex, age, smoking, alcohol consumption, body mass index
(BMI) and oral contraceptive (OC) use. We quantitated the
initiation, propagation and termination phases of each individ-
uals comprehensive TF-initiated thrombin generation curve by
the parameters: time to 10 nM of thrombin, maximum time,
level and rate (MaxR) of thrombin generated and total
thrombin. Results: The greatest risk association was obtained
using MaxR; with a 2.6-fold increased risk at MaxR exceeding
the 90th percentile. The odds ratio (OR) for MaxR was 3.9 in
men, 2.1 in women, and 2.9 in women on OCs. The association
of risk with thrombin generation did not diﬀer by age
(OR:2.8 £ 45 years>OR:2.5), BMI (OR:2.9 £ 26 kg m)2>
OR:2.3) or alcohol use. In both numerical simulations and
empirical synthetic plasma, OC use created extreme shifts in
thrombin generation in both control women andwomenwith a
prior thrombosis, with a larger shift in thrombin generation in
control women. This suggests an interaction of OC use with
underlying prothrombotic abnormalities. Conclusions: Throm-
bin generationbasedupon the individual’s blood composition is
associated with the risk for thrombosis and may be useful as a
predictive marker for evaluating thrombosis on an individual
basis.
Keywords: coagulation proteins, numerical simulations, oral
contraceptives, thrombin generation, thrombosis risk.
Introduction
Determining who is at risk for thrombotic events (venous and
arterial) is difﬁcult because thrombosis is a multicausal
disorder. Risk predictions are now based upon genetic factors
(antithrombin [1,2], protein C [3,4] and protein S [5,6]
deﬁciencies; factor V Leiden [7,8] and prothrombin G20210A
[9,10]), increases in coagulation factors [notably factor VIII
(FVIII) [11], FIX [12], FXI [13], ﬁbrinogen] and environmental
factors (obesity [14,15], oral contraception [16,17], hormone
replacement therapy [17], age [18], alcohol use [19] and
potentially smoking [20]). The heterologous presence of any
of these circumstances in asymptomatic individuals does not
ordinarily necessitate clinical intervention.
The coagulation and ﬁbrinolytic systems are composed of
pro- and anticoagulant and ﬁbrinolytic components that
maintain the balance of blood ﬂuidity. Qualitative or quan-
titative alterations in this hemostatic balance can result in
hemorrhagic or thrombotic diseases. Current laboratory
evaluation techniques cannot fully identify subjects with an
increased risk for venous thrombotic disease and the ranges
considered normal for blood coagulation and ﬁbrinolytic
protein concentrations are broad (>100%). We hypothesize
that an integrated approach that deﬁnes an individual’s
comprehensive coagulation phenotype might prove valuable
in understanding the dynamics of hemostasis and potentially
identify individuals at risk for experiencing a thrombotic
event.
Thrombin generation is essential to hemostasis [21]. Forma-
tion of this key enzyme can be described as occurring in three
phases: initiation, propagation, and termination. During the
initiation phase, exposed or expressed tissue factor (TF) binds
circulating factor (F) VIIa and activates FIX and FX [22].
Minute amounts of thrombin are formed by direct activation
of prothrombin by FXa [23]. Thrombin activates the essential
components (platelets, procofactors FV and FVIII) needed to
produce the major burst of thrombin generation. The resulting
assembly of the membrane bound coagulation enzyme com-
plexes yields the majority of thrombin (96%) during the
propoagation phase [24]. Clot formation occurs when approxi-
mately 10 nM of thrombin–antithrombin is generated and
coincides with the onset of the propagation phase. Any
thrombin formed after this is not detected by standard
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clot-based assays (e.g. the prothrombin time, the partial
thromboplastin time or the activated clotting time [CT]).
Each individual’s blood composition yields a unique clotting
proﬁle [25–27]. Hemostatic disorders, whether genetic, envi-
ronmental or therapeutically induced [27–31], produce major
alterations in these proﬁles. Several empirical technologies have
been developed to directly or indirectly measure the compre-
hensive thrombin generation proﬁle [25,32–34]. However, the
utility of any thrombin generation proﬁles in clinical diagnosis
remains hypothetical.
In this study, we analyzed the theoretical thrombin genera-
tion proﬁles from a case–control study of deep venous
thrombosis (DVT), the Leiden Thrombophilia Study (LETS)
[35] using a numerical simulation model of thrombin genera-
tion [36]. The phases of thrombin generation obtained from the
numerical simulations are evaluated relative to risk of DVT
and compared with an empirical synthetic plasma model using
protein concentrations obtained from the LETS population of
interest.
Materials and methods
Materials
HEPES and EDTA were purchased from Sigma Chemical Co
(St Louis, MO, USA). Brain phosphatidyl serine (PS) and egg
phosphatidyl choline (PC) were purchased from Avanti Polar
Lipids (Alabaster, AL,USA). Recombinant TFwas a gift from
Drs Roger Lundblad and Shu-Len Liu (Hyland division,
Baxter Healthcare Corp, Duarte, CA, USA) and was relipi-
dated (1:2000) in PCPS (25% PS, 75% PC) vesicles by a
previously described protocol [37,38]. Human coagulation
FVII, FX, FIX and FII were isolated from fresh frozen plasma
by usingmethods described by Bajaj et al. [39] and were purged
of trace contaminants and active enzymes as previously
described [40]. Recombinant full-length tissue factor pathway
inhibitor (TFPI) was provided by Dr K. Johnson (Chiron,
Emeryville, CA, USA). Spectrozyme TH was from American
Diagnostica (Greenwich, CT, USA).
Study population
The LETS is a case–control study where 474 patients with an
objectively diagnosed ﬁrst DVT (enrollment Jan. 1, 1988 to
Dec. 31, 1992) were contrasted to the same number of sex and
age-matched controls [35]. The patients were selected from
three anticoagulation clinics in The Netherlands. The controls
were acquaintances of the patients or partners of other patients.
Patients with known malignancies were excluded and all
patients were younger than 70 years. Blood samples were taken
from 6 to 56 months after thrombosis was diagnosed.
Our thrombosis population for this study included 426
individuals (48 individuals were excluded for being on oral
anticoagulation) and a control population of 473 individuals
(1 individual excluded for being on oral anticoagulation). For
risk investigation, we subdivided the populations into groups:
men and women; women without oral contraceptives (OC),
women with OC, age £45 years old and >45 years old,
smokers and non-smokers, alcoholic beverages day)1, 0-, £1-,
2–4-, 5–10-drinks day)1 and body mass index (BMI) of
£26 kg m)2 and >26 kg m)2. When we investigated the
effect of OC (as noted in Table 1), we excluded individuals
who were pregnant, postmenopausal, within 30 days post
partum or had a recent miscarriage at the index date (i.e. the
time of thrombosis for patients). As the median time between
occurrence of DVT and venipuncture was 18 months, we
only evaluated women who either used OC at the index date
and the venipuncture date or did not at both dates. Seven
individuals were excluded from analyses involving alcohol as
information was missing, and three individuals were excluded
from analyses involving BMI who were not 18 at the time of
the blood draw.
Blood collection and coagulation protein analyses
Whole blood (0.9 Vol.) was collected as previously described
[35] from the antecubital vein into Sarstedt Monovette tubes
(Nu¨mbrecht, Germany) containing 0.106 M of trisodium
citrate (0.1 Vol.). Plasma was prepared by centrifugation for
10 min at 2000 g at room temperature and stored in aliquots at
)70 C until assayed.
All protein factor assays were previously performed and are
either activity or antigen-based clinical assays [11,12,35,41–43].
In brief, FII activity was measured by a chromogenic assay
using Echis carinatus venom as an activator [44]. FV:Ag was
measured by an in-house-developed sandwich-type enzyme-
linked immunosorbent assay (ELISA) with two different
monoclonal antibodies, both with a high afﬁnity for the light
chain of activated FV [42]. The FVII and FVIII activities were
measured by one-stage coagulation assays [11,43]. FIX and FX
antigen levels were measured by sandwich ELISA’s using
commercial polyclonal antibodies (Dako A/S, Glostrup, Den-
mark) [12,41]. TFPI total and free antigen wasmeasured with a
commercial ELISA (Asserachrom Total TFPI and Free TFPI,
Diagnostica Stago, Asnieres, France) [45]. The TFPI free
antigen assay is speciﬁc for free-circulating TFPI and does not
detect lipid-bound TFPI. TFPI activity was measured using a
two-stage chromogenic substrate assay as previously described.
All three concentrations of TFPI were evaluated in our model
as we do not know which one is clinically the most signiﬁcant.
All of these percentages were translated into molar concentra-
tions based uponmean published plasma values [46]. Themean
factor levels for the populations are shown in Table 2. Note the
broad range in concentrations observed for the 899 subjects of
this study.
Numerical model of thrombin generation
The numerical model as previously described [36,47] is
composed of selected species that are exposed to picomolar
concentrations of TF and yield active thrombin generation
proﬁles. The mixture of zymogens, cofactors and inhibitors
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are described by 27 equations and 42 rate constants [36].
These numerical simulations of thrombin generation are
comparable with thrombin generation curves observed in
empirical synthetic plasmas and whole blood [31,36,48–50].
For each individual in the LETS population, we used their
protein factor levels for FII, FV, FVII, FVIII, FIX, FX,
Table 1 Comparison of thrombin parameters from the case and control populations
n
MaxR OR
(95% CI)
CT,s
mean (SD)
MaxL, nM
mean (SD)
AUC, lM s
mean (SD)
MaxR, nM s)1
mean (SD)
TimeMaxL,s
mean (SD)
Whole population
Cases 426 2.6 (1.8–3.8) 372 (72) 450 (96) 98 (24) 3.5 (1.0) 698 (87)
Controls 473 393 (80) 412 (83) 92 (19) 3.0 (0.8) 730 (96)
Sex/men
Cases 172 3.9 (2.0–7.5) 382 (68) 442 (89) 98 (23) 3.4 (0.9) 713 (81)
Controls 201 412 (80) 399 (81) 90 (18) 2.9 (0.8) 751 (93)
Sex/women
Cases 254 2.1 (1.4–3.3) 365 (75) 456 (100) 98 (24) 3.6 (1.0) 688 (89)
Controls 272 379 (78) 421 (84) 93 (19) 3.1 (0.9) 714 (96)
Females without OC*
Cases 40 8.8 (3.2–23.7) 357 (83) 464 (121) 101 (35) 3.6 (1.2) 681 (94)
Controls 90 408 (74) 388 (65) 87 (15) 2.8 (0.6) 750 (87)
Females with OC*
Cases 30 2.9 (1.1–7.7) 310 (79) 520 (124) 112 (29) 4.3 (1.2) 623 (95)
Controls 47 311 (71) 472 (92) 100 (21) 3.8 (1.0) 625 (87)
+OC patients vs. –OC controls*
Cases 30 27.7 (9.2–82.9) 310 (79) 520 (124) 112 (29) 4.3 (1.2) 623 (95)
Controls 90 408 (74) 388 (65) 87 (15) 2.8 (0.6) 750 (87)
Age (years)
£45
Cases 209 2.8 (1.7–4.8) 366 (78) 446 (106) 98 (27) 3.4 (1.0) 697 (94)
Controls 223 398 (88) 401 (85) 90 (18) 2.9 (0.9) 738 (106)
>45
Cases 217 2.5 (1.5–4.0) 377 (66) 455 (85) 98 (20) 3.5 (0.9 699 (79)
Controls 250 388 (72) 421 (81) 94 (19) 3.1 (0.8) 723 (87)
Smoke
Yes
Cases 155 2.5 (1.3–4.5) 376 (74) 449 (107) 99 (28) 3.4 (1.0) 707 (90)
Controls 168 392 (85) 412 (82) 92 (19) 3.0 (0.8) 732 (102)
No
Cases 271 2.7 (1.7–4.3) 369 (71) 451 (89) 98 (21) 3.5 (0.9) 693 (85)
Controls 305 393 (78) 411 (84) 92 (19) 3.1 (0.8) 729 (93)
Alcohol
None
Cases 135 3.2 (1.6–6.3) 372 (76) 458 (91) 98 (20) 3.6 (1.0) 696 (93)
Controls 111 384 (77) 417 (79) 93 (18) 3.1 (0.8) 722 (90)
£1
Cases 175 2.0 (1.2–3.4) 374 (73) 439 (91) 96 (24) 3.4 (0.9) 699 (85)
Controls 222 394 (82) 410 (83) 91 (19) 3.0 (0.9) 732 (103)
2–4
Cases 95 2.7 (1.2–6.0) 370 (68) 453 (94) 99 (23) 3.5 (0.9) 699 (84)
Controls 124 396 (82) 408 (87) 91 (19) 3.0 (0.8) 731 (90)
5–10
Cases 13 6.3 (0.6–64.9) 349 (69) 511 (174) 119 (51) 4.0 (1.7) 682 (90)
Controls 11 395 (92) 425 (101) 96 (23) 3.1 (0.8) 736 (107)
BMI kg m)2
£26
Cases 206 2.9 (1.6–5.0) 386 (78) 429 (91) 93 (21) 3.3 (0.9) 712 (91)
Controls 275 409 (83) 394 (78) 88 (17) 2.9 (0.8) 748 (99)
>26
Cases 216 2.3 (1.4–3.8) 356 (61) 473 (95) 103 (26) 3.7 (1.0) 681 (77)
Controls 193 370 (72) 437 (83) 97 (20) 3.3 (0.9) 704 (88)
OR, odds ratio calculated at the 90% cut oﬀ point using MaxR; BMI, body mass index; OC, oral contraceptives.
*These women were premenopausal, age 15–49, with no recent miscarriage, pregnancy, within 30 days post partum or use of depot contraceptives
only and were only selected when OC use at the index date was the same as at the time of the blood draw.
The OR was calculated at a 75th percentile, since no control individuals were present at a 90th percentile cut-oﬀ point.
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antithrombin (AT) and TFPI (active, free, and total) and
generated active thrombin proﬁles that represent how much
dynamic thrombin would have been generated in each
individual at the time of their blood draw. Each individual’s
blood factor concentration was entered into the computer
database, Clot Speed II [36]. Simulated reactions were
initiated with a 5 pM TF stimulus and solved for active
thrombin over 1200 s. Active thrombin is displayed as a
combination of thrombin and meizothrombin weighted
according to meizothrombin’s activity toward synthetic
thrombin substrates. The outputs of these active thrombin
curves are evaluated by parameters that describe the initi-
ation, propagation and termination phases of thrombin
generation: maximum level of thrombin generation (MaxL),
maximum rate of thrombin generated (MaxR), time to 10 nM
of thrombin (clot time, CT), time to maximum level of
thrombin generated (TimeMaxL) and total thrombin gener-
ated (area under the curve, AUC) (Fig. 1).
Synthetic plasma analyses of thrombin generation
The procedure used is a modiﬁcation of Lawson et al. [51] and
van’t Veer and Mann [40] and involves mixing proteins, lipids
and relipidated TF to produce a synthetic equivalent of in vivo
thrombin generation. I. Procofactor solution. Relipidated TF
(10 pM; molar ratio PCPS:TF ¼ 5000) is incubated with
4 lM PCPS in HBS (20 mM of HEPES and 150 mM of NaCl,
pH 7.4) and 2 mM of CaCl2 for 10 min at 37 C. FV and
FVIII at selected mean concentrations from the LETS
population are added prior to the initiation of the reaction.
II. Zymogen-inhibitor solution. FII, FVII/FVIIa, FX, FIX,
FXI, TFPI, and AT at selected mean concentrations from the
LETS population are preheated in HBS, 2 mM of CaCl2 at
37 C for 3 min. The reaction is started by mixing equal
volumes of both solutions resulting in the desired concentra-
tion of the zymogens, pro-cofactors and inhibitors, 5 pM TF,
2 mM of CaCl2 and 2 lM of PCPS. Following the start of the
reaction, at selected time points, a 10 lL aliquot is withdrawn
from the reaction mixture and quenched in 20 mM of EDTA
in HBS (pH 7.4) containing 0.2 mM of spectrozyme TH and
assayed immediately for thrombin activity. The hydrolysis of
the substrate is monitored by the change in absorbance at
405 nM by using a Vmax spectrophotometer (Molecular
Devices, Sunnyvale, CA, USA).
Four experiments were performed: (a) control women not on
OC (mean of n ¼ 90; FII: 1.4 lM, FV: 25 nM, FVII: 10 nM,
FVIII: 0.82 nM, FIX: 83 nM, FX:153 nM, AT: 3.4 lM,
TFPI:2.9 nM); (b) control women on OC (mean of n ¼ 47;
FII: 1.5 lM, FV: 22 nM, FVII: 12 nM, FVIII: 0.87 nM, FIX:
103 nM, FX:189 nM, AT: 3.2 lM, TFPI:2.3 nM); (c) women
with DVT not on OC (mean of n ¼ 40; FII: 1.5 lM, FV:
27 nM, FVII: 12 nM, FVIII: 0.98 nM, FIX: 104 nM,
FX:183 nM, AT: 3.3 lM, TFPI:2.9 nM); (d) women with
DVT on OC (mean of n ¼ 30; FII: 1.6 lM, FV: 22 nM, FVII:
12 nM, FVIII: 0.96 nM, FIX: 108 nM, FX:194 nM, AT: 3.1 lM,
TFPI:2.4 nM).
Statistical analysis
We evaluated the effect of variables used to describe the
initiation, propagation and termination phases of thrombin
generation on the risk of developing DVT by determining the
odds ratios (OR). We calculated ORs and their 95%
conﬁdence intervals (95% CIs) using the 90th percentile
levels for MaxL, MaxR, and AUC. The time variables,
TimeMaxL and CT, were investigated at the 10th percentile
in order to investigate the faster CTs, which are prothrom-
botic. To adjust for confounding by the other propagation
variables (MaxR, MaxL, AUC, TimeMaxL), we used a
logistic regression model including all other propagation
variables (except CT) in the model as covariates when
calculating the OR for MaxR, MaxL, AUC and TimeMaxL.
Subsequently, we calculated crude ORs and 95% CIs using
the 90th percentile levels for MaxR for subgroups i.e. men,
women, women with or without OC, individuals older or
Table 2 Inventory of the LETS case/control population
Protein
Case population Control population
Percentage
mean (SD) Range
Percentage
mean (SD) Range
FII 108 (17) 67–178 104 (15) 63–153
FV 133 (35) 41–305 131 (33) 47–302
FVII 114 (25) 53–200 110 (22) 41–171
FVIII 141 (35) 53–318 122 (33) 49–232
FIX 109 (26) 63–209 103 (21) 52–188
FX 107 (20) 58–174 103 (17) 49–163
AT 99 (11) 67–143 99 (10) 63–125
TFPI total 94 (21) 35–159 92 (21) 46–171
TFPI active 118 (18) 62–219 117 (17) 72–198
TFPI free 89 (32) 23–211 85 (32) 20–275
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Fig. 1. A numerical simulation of an active thrombin proﬁle illustrating
the thrombin parameters. The clinical proﬁle on an individual containing
the concentration for FII, FV, FVII/VIIa, FVIII, FIX, FX, AT and TFPI
was used to initiate coagulation in the presence of a 5 pM TF stimulus.
Active thrombin was evaluated using the parameters, time to 10 nM of
thrombin (CT), MaxR, MaxL, TimeMaxL and AUC.
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younger than 45 years, smokers or non-smokers, and differ-
ent classes of alcohol use or BMI.
Results
Thrombin generation profiles
The mean thrombin generation and the 95% CI in the control
and thrombosis population are seen in Fig. 2, panel A. Active
TFPI values, rather than total or free TFPI, were used in the
simulation of these curves. The control population had a mean
CT of 393 s (SD:80), a mean MaxL of 412 nM (SD:83 nM), a
mean MaxR of 3.0 nM s)1 (SD:0.8 nM s)1), a mean AUC of
92 lM (SD:19 lM) and a mean TimeMaxL of 730 s (SD:96 s)
(Table 1). The thrombosis population was shifted toward a
slightly faster CT of 372 s (SD:72 s), TimeMaxL of 698 s
(SD:87 s) and MaxR of 3.5 nM s)1 (SD:1.0 nM s)1), and a
slightly higher MaxL 450 nM (SD:96 nM) and AUC 98 lM
(SD:24 lM).
Thrombin parameters as predictors of thrombosis
We investigated the thrombin generation parameters for their
effect on the risk of developing DVT. Using a 90% cut off
point for each of the individual variables, the crude OR for
developing a DVT was 2.6 (95% CI: 1.8–3.8) for MaxR, 2.4
(95% CI: 1.7–3.5) for MaxL, 2.2 (95% CI: 1.5–3.2) for
AUC, 1.6 (95% CI: 1.1–2.4) for CT at a 10% cut-off point
and 1.6 (95% CI: 1.1–2.3) for TimeMaxL. When we adjusted
the propagation variables MaxR, MaxL, AUC and Time-
MaxL for the effect of the other propagation variables,
MaxR still displayed the highest OR at 2.6 (95% CI: 1.4–4.7)
when adjusted for MaxL, AUC and TimeMaxL. The
adjusted OR was 1.0 (95% CI: 0.5–1.9) for MaxL, 1.5
(95% CI: 0.9–2.5) for AUC and 0.8 (95% CI: 0.5–1.3) for
TimeMaxL. When total or free TFPI values were used,
rather than active TFPI concentrations, MaxR also yielded
the highest OR (1.8 in the model with total TFPI and 2.9 in
the model with free TFPI).
Association of thrombin generation parameters with risk
in relation to classical risk factors
Individuals with DVT of both sexes had a faster CT,
TimeMaxL and MaxR, a higher MaxL and a greater AUC
than controls of the same sex (Table 1). Using MaxR at the
90% cut off point, men showed anORof 3.9 (95%CI: 2.0–7.5)
and women an OR of 2.1 (95% CI: 1.4–3.3). We studied the
effect of OC use by selecting women who were premenopausal,
aged 15–49, with no recent miscarriage or pregnancy and
within 30 days post partum. In this group, the OR for MaxR
exceeding the 90th percentile was 2.9 (95% CI: 1.1–7.7). In
women who did not use OC, cases clotted faster than controls
(mean difference 51 s, 95% CI: 21–81 s), had higher levels of
thrombin (mean difference 76 nM, 95% CI: 36–116 nM)
generated at a faster rate and time (mean difference 69 s,
95%CI: 35–103 s) andmore total thrombin was present (mean
difference 14 lM s, 95% CI: 3–25 lM s) (Fig. 2, Panel B). As
none of the controls had levels of MaxR above the 90th
percentile, we calculated the OR for developing DVT at the
75th percentile where the OR was 8.8 (95% CI: 3.2–23.7) for
women without OC use.
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Fig. 2. Comparison of selected active thrombin proﬁles for the control and deep vein thrombosis (DVT) populations. These active thrombin generation
curves are shown as the mean and 95% conﬁdence interval of the population selected. (A) The DVT population (n ¼ 426, left curve) is compared with the
control population (n ¼ 473, right curve). (B) Women without OCs are compared between the DVT population (n ¼ 40, left curve) and the control
population (n ¼ 90, right curve). (C) Women with OCs are compared between the DVT population (n ¼ 30, left curve) and the control population (n ¼
47, right curve). (D) Women with DVT on OCs (n ¼ 30, left curve) and the control population not on OCs (n ¼ 90, right curve) are compared.
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Contraceptive use consistent between the index date and the
venipuncture date affected both the DVT and control popu-
lations by increasing the thrombin parameters. However, in
women with a DVT (Fig. 3B), thrombin parameters were not
as increased upon OC use as in the control population
(Fig. 3A) upon OC use. The increase in thrombin generation
parameters with OC use in women with DVT was as follows:
CT by 47 s (95% CI: 9–85 s), MaxR by 0.7 nM s)1 (95% CI:
0.1–1.3 nM s)1) and TimeMaxL by 58 s (95% CI: 13–103 s).
No signiﬁcant decrease was seen for MaxL (mean difference
56 nM, 95%CI: )2 to 114 nM) and AUC 11 lM s (95%CI: )4
to 26 lM s). In the control women upon OC use, the thrombin
parameters increased as follows: CT by 97 s (95% CI:
72–122 s), MaxL by 84 nM (95% CI: 54–114 s), AUC by
13 lM s (95% CI: 6–20 lM s), MaxR by 1.1 nM s)1 (95%
CI: 0.8–1.4 nM s)1) and TimeMaxL by 125 s (95% CI:
94–156 s).
The OR for DVT of MaxR was 2.9 in women on OC
hormones with an increase in MaxR of 19% in women with
DVT on OC vs. those not on OC and 36% in control women
on OC vs. those not on OC. As well, women with a DVT who
used OCs had a 54% faster MaxR than control women who
did not use OC (Fig. 2, panel D). Their coagulation proﬁles
were increased over the controls by: CT: 98 s (95% CI:
66–130 s),MaxL: 132 nM (CI: 86–178 nM), AUC: 25 lM s (CI:
14–36 lM s), MaxR: 1.5 nM s)1 (95% CI: 1.1–1.9 nM s)1),
TimeMaxL: 127 s (95% CI: 89–165 s). The OR at the 75th
percentile for women with DVT on OC use vs. control women
not on OC use was 27.7 (95% CI: 9.2–82.9).
The mean factor levels of the OC populations (thrombosis
and control) shown in Fig. 3A and B were used in empirical
reconstructed plasma experiments with the same TF stimulus
used in the numerical simulations. These results are shown in
panel B and C of Fig. 3. By recapitulating the mean proco-
agulant and anticoagulant protein proﬁles of the LETS
individuals identiﬁed for each curve on a phospholipid surface
(see Materials and methods), we obtain similar patterns of OC
effect on thrombin generation that is seen in the numerical
simulations. In both the control and women with DVT,
thrombin generation is accelerated in women that used OC.
For the control women not on OC use vs. the control women
on OC use, the thrombin parameters increased from: 312 s to
243 s for CT, 1 nM s)1 to 1.9 nM s)1 for MaxR, 236 nM to
262 nM for MaxL, 54 lM s to 62 lM s for AUC and 540–420 s
for TimeMaxL (Fig. 3, panel C). In comparing women with a
DVT not on OC use vs. women with DVT on OC use, the
thrombin parameters increased from: 219 s to 195 s for CT,
1.6 nM s)1 to 1.8 nM s)1 for MaxR, 289 nM to 299 nM for
MaxL, 69 lM s to 68 lM s for AUC and 420–360 s for
TimeMaxL (Fig. 3, panel D). The most prothrombotic proﬁle
was seen in women who had had a DVT and were still using
OCs at the time of the blood draw, followed by healthy control
women using OCs at the index and blood draw date. The least
prothrombotic curves were in healthy women not using OCs.
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Fig. 3. Oral contraceptive (OC) eﬀect on theoretical and empirical thrombin generation. Thrombin generation simulations under a 5 pM TF stimulus are
shown as the mean and the 95% conﬁdence interval for (A) control women with (n ¼ 47) and without (n ¼ 90) OC use and (B) Women with DVT with
(n ¼ 30) and without (n ¼ 40) OC use. The mean factor levels of the selected populations shown in panel A and Bwere recapitulated in a synthetic plasma
model with 2 lM of phospholipids and a 5 pMTF stimulus and are shown in panel C andD. (C) Control women not on OC (mean of n ¼ 90; FII: 1.4 lM,
FV: 25 nM, FVII: 10 nM, FVIII: 0.82 nM, FIX: 83 nM, FX:153 nM, AT: 3.4 lM, TFPI:2.9 nM) are compared with control women on OC (mean of n ¼ 47;
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As MaxR is the most predictive parameter in the numerical
model, our empirical experiments show that OC use effected
MaxR in the control women by a 90% increase, whereas in the
DVT population, OC use effected MaxR by only 12%. Thus,
this demonstrates that OC use effects empirically generated
thrombin generation to a greater degree in control women than
women with DVT as was also determined with numerically
simulated thrombin generation. The similarities between the
empirical experiments and the numerical simulation results also
validate the rate constants chosen for use in the computational
model for the components that are present which include, FII,
FV, FVII, FVIII, FIX, FX, AT, and TFPI.
Thrombin generation proﬁles were associated with throm-
bosis for all ages tested: using highMaxR yielded an OR of 2.8
for individuals <45 years old and an OR of 2.5 for individuals
>45 years old (Table 1). Thrombin generation was associated
with risk for different classes of obesity: among those with a
BMI £26 kg m)2, highMaxR showed an OR of 2.9, and 2.3 in
those with a BMI >26 kg m)2. The association between
thrombin generation and the risk of developing DVT for
different classes of alcohol consumption was: 6.3 (95% CI:
0.6–64.9) for 5–10-drinks day)1, 2.7 (95% CI: 1.2–6.0) for
2–4-drinks day)1, 2.0 (95% CI: 1.2–3.4) for £1 drink per day
and 3.2 (95% CI: 1.6–6.3) for the non-drinking population.
Note that the 95%CI in all of these categories is wide. The OR
for developing DVT associated with thrombin generation was
2.5 in smokers and 2.7 in non-smokers.
Discussion
The predicted composition-based capacity for thrombin gen-
eration in response to a TF challenge represents an integrative
method to identify an individual’s propensity for developing
DVT. The most inﬂuential variable was the MaxR, which,
corrected for by all propagation phase variables (except CT),
resulted in an OR of 2.6 (95%CI: 1.8–3.8) for the highest 10%
of MaxR values. The use of the numerical simulation model
allows for the combination of the results of the individual
reactions into a complete ensemble describing not only the
observed progress in thrombin formation but also the activa-
tion progress for each of the proteins as intermediates in the
path toward thrombin formation. These results were veriﬁed by
recapitulating thrombin generation based upon the protein
proﬁles of the speciﬁed LETS population in a synthetic plasma
model. Therefore, the individual’s hemostatic proﬁle is trans-
lated into a deﬁned pattern, which can be used as an evaluation
tool for thrombosis risk, potentially with the ability to inﬂuence
clinical decision making. Our results show that there may exist
subthreshold venous thrombosis states in individuals (i.e. OC
use) that depend only on a trigger, which will create a
heightened prothrombotic state that presents itself upon
challenge. Thus, illustrating that evaluating comprehensive
thrombin generation via an individual’s protein proﬁle can be a
measure of an individual’s prothrombotic state.
Understanding the relationship of TF-initiated thrombin
generation to clinical outcome has been hindered by the
absence of comprehensive assays and in the ability to collect
blood from patients during a hemostatic challenge. The use of
the numerical simulation model enables the estimation of TF-
initiated dynamic thrombin generation using available tools
(i.e. patients factor levels). The numerical simulation method
thus allows the evaluation of well-studied clinical databases,
such as the LETS population, and compares dynamic throm-
bin generation retrospectively to determined clinical pheno-
types. Although these studies do not include the contribution of
the anticoagulant protein C pathway, the contribution of
platelets, the contact pathway or the vasculature, it does
include all the plasma pro- and anticoagulant proteins of the
TF pathway to thrombin generation that are currently
evaluated in laboratories.
In this study, we translated the active thrombin proﬁles into
thrombin parameters that incorporate the initiation, propaga-
tion and termination phases of thrombin generation. The
principal regulator of the initiation phase of thrombin genera-
tion is TFPI, the stoichiometric inhibitor of the FVIIa–TF–
FXa enzyme-product complex. Thrombin generation simula-
tions performed using either active, total or free TFPI values
yielded similar risk estimates. Previously, it has been reported
that for the LETS population, low levels of TFPI, especially
low TFPI-free and total antigen in plasma, constituted a risk
factor for DVT [45]. In the numerical system, the difference
between TFPI subsets is small. In previous numerical simula-
tions for healthy individuals (the LETS control group), the
effect from any individual protein on thrombin generation
outcome was <9% [27]; thus, it is the interplay between the
procoagulants and the anticoagulants that determine the extent
of thrombin generation.
MaxR was the most useful predictor of DVT. This
parameter incorporates the velocity at which thrombin is
formed, and is obtained as the slope of the thrombin generation
curve (Fig. 1). The range of meanMaxR in the subpopulations
was from 2.8 to 4.3 nM s)1; with the cases between 3.3 and
4.3 nM s)1 and the controls between 2.8 and 3.8 nM s)1.
Previous studies of genetic bleeding disorders have shown that
in hemophilia the MaxR ranges from 0.2 to 0.5 nM s)1 [52].
From these studies, we can begin to evaluate a thrombotic
point or threshold using MaxR in healthy individuals.
During investigation of the inﬂuence of MaxR relative to
risk factors, sex, age, BMI, OC use, alcohol consumption and
smoking, we found that MaxR was associated with risk in all
strata of these factors. MaxR was highest in patients using
OCs. OC use is an established risk factor for both venous and
arterial thrombosis [16,53,54]. We found that OC use strongly
increases a woman’s thrombin generation proﬁle by affecting
all three phases of TF-initiated thrombin generation in both
case and control women. All of these women were premeno-
pausal, age 15–49, who had no recent miscarriage, were not
pregnant, nor within 30 days post partum and were only
selected when OC use at the index date was the same as at the
time of the blood draw. Previously, Bloemenkamp et al. [55]
showed that OC use had a more pronounced hemostatic effect
in women who had suffered DVT with regard to the levels of
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FVII, FXII, protein C, AT, protein S and APC-sr than in
healthy women, suggesting the existence of hyperresponders.
Heightened thrombin generation in healthy women on OC use
has also been shown experimentally using special ﬂuorogenic
thrombin substrates and monitoring clotting in PPP and PRP
[56]. We see comparable results, in that women with a DVT
that are on OC use have the most pronounced acceleration of
thrombin generation. Our results in this study also indicate that
OC use had a larger impact on thrombin generation proﬁles in
control women than women with a diagnosed DVT. As all of
the simulated thrombin generation curves are initiated with the
same amount of TF stimulus, shifts in the thrombin generation
curve are caused by other factors that are present in these
individuals. OC potentially causes a subclinical prothrombotic
phenotype in these healthy control women that may become
apparent when presented with a challenge. As exogenous
hormones are used by more than a hundred million women
worldwide as OCs or for postmenopausal hormone replace-
ment, methods for stratiﬁcation of thrombotic risk are
essential.
As venous thrombosis is deﬁned by a vasoocclusive event,
the differentiation of cases and controls is of temporal quality.
The accidental occurrence of precipitating environmental
factors, e.g. trauma, may lead to an individual becoming a
case, while another, with the same thrombin generation proﬁle,
in the absence of those factors, will remain a control. This
ampliﬁcation to generate thrombin in the controls may be only
differentiated from the cases by time. Hemophilia patients with
severe FVIII deﬁciency do not all have similar bleeding
pathology. Potentially, the more thrombin they can generate,
the lower the bleeding risk. Conversely, the more thrombin a
healthy individual can produce, the higher the thrombotic risk
when a risk situation occurs. Our model uses the combined
inﬂuence of all of the plasma pro- and anticoagulants of the TF
pathway on dynamic thrombin generation. Overall, our results
suggest that evaluating hypothetical thrombin generation
based upon the individual’s blood composition may be useful
as a predictive marker for evaluating thrombosis.
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